The Oasis study group has presented initial results of the CURRENT-OASIS 7 clinical trial at the European Society of Cardiology congress in Barcelona. CURRENT-OASIS 7 clinical trial evaluated
Watson Pharmaceuticals has announced that its subsidiary, Watson Laboratories has received approval from the United States Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA)
Huimin Kong chief executive officer of BioHelix said that the company hopes to move into its new space in November 2009, after it completes a lab that is
US drug reviewers have questioned a Genzyme study meant to back wider use of the Clolar leukemia drug. Clolar is approved for treating a type of leukemia in
Orexo has signed an exclusive worldwide licensing agreement with Novartis to develop and commercialise a novel product related to Orexo’s OX17 program. Under the terms of the agreement,
Eurand has received FDA approval of its New Drug Application (NDA) for ZENPEP (pancrelipase) delayed-release Capsules for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic
Sinovac has reported that the Beijing Public Health Bureau has selected Sinovac to supply Anflu, Sinovac’s seasonal influenza vaccine. Developed and manufactured by Sinovac, Anflu is said to
Facet Biotech and Trubion have signed an agreement for the joint worldwide development and commercialisation of TRU-016. TRU-016, a product candidate in phase 1 clinical development for chronic
Boehringer Ingelheim has revealed that the new analysis of the UPLIFT trial, shows that tiotropium administered to Chronic Obstructive Pulmonary Disease (COPD) patients with moderate disease severity produced
BTG has announced the sale of HySolv drug delivery technology to Novartis Pharma for an initial payment of $0.75m and potential additional future milestone payments of up to
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.